Correlation Between Kymera Therapeutics and Immunovant

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Immunovant at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Immunovant into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kymera Therapeutics and Immunovant, you can compare the effects of market volatilities on Kymera Therapeutics and Immunovant and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Immunovant. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Immunovant.

Diversification Opportunities for Kymera Therapeutics and Immunovant

0.29
  Correlation Coefficient

Modest diversification

The 3 months correlation between Kymera and Immunovant is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Immunovant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunovant and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Immunovant. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunovant has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Immunovant go up and down completely randomly.

Pair Corralation between Kymera Therapeutics and Immunovant

Given the investment horizon of 90 days Kymera Therapeutics is expected to generate 1.01 times more return on investment than Immunovant. However, Kymera Therapeutics is 1.01 times more volatile than Immunovant. It trades about 0.04 of its potential returns per unit of risk. Immunovant is currently generating about -0.04 per unit of risk. If you would invest  4,617  in Kymera Therapeutics on September 1, 2024 and sell it today you would earn a total of  68.00  from holding Kymera Therapeutics or generate 1.47% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Kymera Therapeutics  vs.  Immunovant

 Performance 
       Timeline  
Kymera Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kymera Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable primary indicators, Kymera Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Immunovant 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Immunovant is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Kymera Therapeutics and Immunovant Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kymera Therapeutics and Immunovant

The main advantage of trading using opposite Kymera Therapeutics and Immunovant positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Immunovant can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovant will offset losses from the drop in Immunovant's long position.
The idea behind Kymera Therapeutics and Immunovant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Share Portfolio
Track or share privately all of your investments from the convenience of any device